Guidelines and critical pathways for severe hospital-acquired pneumonia

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, β-lactam/β-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.

Original languageEnglish (US)
Pages (from-to)412S-418S
JournalChest
Volume119
Issue number2 SUPPL.
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Critical Pathways
Pneumonia
Guidelines
meropenem
Anti-Bacterial Agents
Physicians
Lactams
Quality of Health Care
Therapeutics
Decision Making
Patient Care
Morbidity
Costs and Cost Analysis
Survival
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{99a3c463c7434904a8eb53c3db32e3ef,
title = "Guidelines and critical pathways for severe hospital-acquired pneumonia",
abstract = "Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, β-lactam/β-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.",
author = "Stanley Fiel",
year = "2001",
month = "1",
day = "1",
doi = "10.1378/chest.119.2_suppl.412S",
language = "English (US)",
volume = "119",
pages = "412S--418S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2 SUPPL.",

}

Guidelines and critical pathways for severe hospital-acquired pneumonia. / Fiel, Stanley.

In: Chest, Vol. 119, No. 2 SUPPL., 01.01.2001, p. 412S-418S.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Guidelines and critical pathways for severe hospital-acquired pneumonia

AU - Fiel, Stanley

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, β-lactam/β-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.

AB - Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, β-lactam/β-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.

UR - http://www.scopus.com/inward/record.url?scp=0035110287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035110287&partnerID=8YFLogxK

U2 - 10.1378/chest.119.2_suppl.412S

DO - 10.1378/chest.119.2_suppl.412S

M3 - Article

C2 - 11171778

AN - SCOPUS:0035110287

VL - 119

SP - 412S-418S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2 SUPPL.

ER -